Salicylic acid derivatives useful as glucocerebrosidase activators

摘要

Compounds of Formula (I) and the pharmaceutically acceptable salts thereof are disclosed. The variables. R1-R13, m, n, o, and p are disclosed herein. The compounds are useful for treating Gaucher disease and inhibiting the onset of Gaucher disease symptoms in a patient having a GBA gene mutation and for treating Parkinson's disease. Pharmaceutical compositions containing compounds of Formula (I) and methods of treatment comprising administering compounds of Formula (I) are also disclosed.;

主权项

1. A compound o pharmaceutically acceptable salt thereof, of Formula (I): wherein: m is 1, n is 1, o is 1, and p is 0; R1 is a halogen, C1-C2alkyl, or C1-C2alkoxy; R2 is hydrogen or C1-C4alkyl; R3 and R4 are independently selected from hydrogen, halogen, amino, cyano, C1-C4alkyl, C1-C4alkoxy, mono- and di-C1-C4alkylamino, C1-C2haloalkyl, and C1-C2haloalkoxy; R5, R5′, R9, R9′, and R12, R12′ are independently chosen at each occurrence from hydrogen, fluoro, phenyl, (C3-C6cycloalkyl)C0-C2alkyl, and C1-C4alkyl; R6 is one substituent selected from hydrogen, halogen, hydroxyl, amino, cyano, C1-C6alkyl, C1-C6alkoxy, mono- and di-C1-C4alkylamino, C1-C2haloalkyl, and C1-C2haloalkoxy; R7, R10, and R13 are each 0 or 1 or more substituents independently chosen from halogen, hydroxyl, amino, cyano, C1-C6alkyl, C1-C6alkoxy, mono- and di-C1-C4alkylamino, C1-C2haloalkyl, and C1-C2haloalkoxy; and R8 and R11 are independently chosen from hydrogen and C1-C4alkyl.